CVD Risk Reduction and Lipid Management - (Page 5)
Steering Committee Disclosures
The Steering Committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
• Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA: Advisory Board: Abbott, Amgen, AstraZeneca, LipoScience Inc., Sanofi-Aventis; Stock Holdings: LipoScience Inc. • Michael Miller, MD, FACC, FAHA: Consultant: Amarin, Abbott, Roche; Research: Abbott, Merck, Roche; Speaker: Merck • Eliot A. Brinton, MD, FAHA, FNLA: Consultant: Abbott, Amarin, Daiichi-Sankyo, Essentialis, GlaxoSmithKline, Merck, Roche; Speaker: Abbott, Amarin, Daiichi-Sankyo, GlaxoSmithKline, Merck; Researcher: Abbott, Amarin, Merck; Scientific Advisory Board: Atherotech
Table of Contents for the Digital Edition of CVD Risk Reduction and Lipid Management
CVD Risk Reduction and Lipid Management
If you would like to try to load the digital publication without using Flash Player detection, please click here.